{"id":890396,"date":"2025-09-29T16:03:20","date_gmt":"2025-09-29T20:03:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/"},"modified":"2025-09-29T16:03:20","modified_gmt":"2025-09-29T20:03:20","slug":"arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/","title":{"rendered":"Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WESTLAKE VILLAGE, Calif., Sept.  29, 2025  (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025 financial results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will also host a virtual Investor Day the same day at 10:30 a.m. ET.<\/p>\n<p>In addition to discussing third quarter 2025 financial results, the Investor Day will feature:<\/p>\n<ul type=\"disc\">\n<li>An in-depth look into the Company\u2019s strategy for long-term, sustained growth for ZORYVE\u00ae (roflumilast)<\/li>\n<li>A detailed review of clinical development activities and advancements for new ZORYVE indications and ARQ-234<\/li>\n<li>An overview of the Company\u2019s capital allocation strategy and financial outlook<\/li>\n<\/ul>\n<p>The event will feature presentations from Arcutis Biotherapeutics\u2019 management team as well as a fireside chat with Douglas DiRuggiero, PA-C, DMSc, founding president of the Georgia Dermatology Physician Assistant Society.<\/p>\n<p>Following formal presentations, management will host a Q&amp;A session.<\/p>\n<p>A live webcast of the event and the presentation materials will be available on the\u00a0\u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gASScIicZqO7ugmckiu7DVaTvM4kQjCiwJuYIVGH6WsXJUVeGhdp5uceqpcCtDiWUawgb1NTxxZvKKtOvinImRzAy9FopRG_wBqZ27f1MurFtdcxUor869Hs1XxTyWTe6-wilF_UxnucYvf2G1i68A==\" rel=\"nofollow\" target=\"_blank\">Events<\/a>\u201d\u00a0section of the Company\u2019s website. An archived replay of the webcast will be posted on the Arcutis investor website following the event.<\/p>\n<p>\n        <strong>About Arcutis\u00a0<\/strong><br \/>\n        <br \/>Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis\u2019 unique dermatology development platform coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=41Yl6ipTPiLfmEtMn_HNp2n_gPSqgtIq0pdS18xBVS2rcHndO9Y2fLYWO_RYbR6bRqTojdtaPtFqXc6FCA86D3RcjigQzQem6_Oy6_ZOaVL-SpCxhYzjigom7Wz7bx9gn_zH69uSsumaDplaWh4bXKxrVinDkgHNSdubqhvF2nvjTuL40uktN7UksWGi2RHrjB-YB12tJlWkyuvBMqkrTWV0b9WZkdnlKF7u8bXOn-8NKzFn2gmS9e2RFNnCAANirRtXivvDYFXegvpH73x0aanbyPuE5eEzBW398Y_01wT4JF6dYW08AAmseWsKWntNkUzUU7n_zZERJXFZP0aLCY0PrDSmiqE283v6jujq_qvWigI5tL29qJRBqC3ScZpif_1-YLMTiXEpuJ0se6mNVKGi6tBp1RCXmn1A2HKotawMAAWSu0Qt7zIMHqzpgBfge5y_UcHVUS0ItkpXGgJStvBLDmNIcGbndGyqiAQpHVY=\" rel=\"nofollow\" target=\"_blank\"><strong>www.arcutis.com<\/strong><\/a>\u00a0or follow Arcutis on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=25E8IajVgMSxnOKvocxeFTa9aPl_8hl41NGNDbBiY6hmKs8vztFW3gm6zgI9guNH-852rW_axBx8piexqV-sNo9_EzCPhgHLQ_QBOY-b95S-OVKZz1fdqcnz9iONk4-sm123w8XLVehilXNQPSzx5_5i_9zowivPj0UoBCRxL-cV2VnA6-y40w5InCk8WQHQS_yp6PdD5AuLAA0Nl6YiKksB_DGpjigV340NKDeLTtGNqtMKMEikwhkXAtj2lMie3psRdcB_v8CFCvBB_gNeRsV5r5ONLhQ3RIRjtCusDg_0MOG2hn1eIneIh54ZhrcD5e83qb21zBQsYsm_TCF7ALP1sFlT1_IPHU9WW3zzpbXOBGoTVXKqeAmSzXma7loN-FdZX5LyNU2HY5ZuWXUTWP70croOmXvNO9SYPQUFkZkBVNqbmSC1rzr84BDioHn6jyp4enNPq8hGnGF7MGcdtnmzYqHldq6tEyOQCXDt20c=\" rel=\"nofollow\" target=\"_blank\"><strong>LinkedIn<\/strong><\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zhlEz2P1p9da9-KJBbE8F7m2rYvKiJoluNC0GKqfUkehI2CKPF_cq1FkPUyVDsJ1oDblPNhimw3zTCrk92KXEs4r_LTc1nmXiHOrJRzA2So1pKTGoSZGmWs0itlyuXqM-Q8Q10ml0y2465NYi04RmIChCOOU8AzYAwmoNBx0BHadeTc2pU-6yKdABu7gyS8gDLvKdsQT4H0P2RRqMsQIy5WHdRMzPFpCEBSVdlN8OGkUVnFnMiQYzhbSl5S9_UScDMsGhnPQajPoiXblKW2fAR9VJoBy4dcMMi5KQoB_A-SCSO0dS94XHzCsSX8CEc6-Gk_HGTAs9DnxSPcWsli-DJxHpzLPWEuqy2ppUt7dnVhS6uoDFDUE7UerqMoV_y4fX-cZ1EYWjNFUk7RrE8BpkdFUPyh1AJl8DG1dEzdEBH6prIc5yOqDzLgT1-DV7Xej\" rel=\"nofollow\" target=\"_blank\"><strong>Facebook<\/strong><\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JSoR8ZBGRYWhP1wkwQhx7vwQgY4jGqblwiIGkYObnE6QWhEBlEYWE-9UoWYsmQW_JeGyDks60PVUeNS_7N6xnQuc1bzXQgB7smPbpKlYpWFY4uvo8xElldhiAhgSvm2ioahLs8J6xpBe1bs_l7DnlC2UkwPGu-dzx66cW2vXY4k6BzrHrjpuNiVlOkfHbWYeEdP64XZ8s2yEGuio7HuKijJoGjhXnq9w8g-_9PeUA2Q6fq2HQ_C71faE9KzDDfLfq7qn30JBh44KNavvEcL4cwiCZ4L_pT2WmzzpeXwcjhdED8H4x5jY78XbUXSLa-wvxcvvQRP53SyF8IQdrDQV1DFuQKea2WeChvUv_HI4q3A9FggExiLEbyC8zIHeTQgQUIu68hnYf8pTlZRIWN1mtYgcpjrQLCcEBWw9s25RAbQbFX8w5EKV7xt5ExpJ2zM_\" rel=\"nofollow\" target=\"_blank\"><strong>Instagram<\/strong><\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tTjgApPY35VDPmM9_1I5VwzjZD45qARPaceVUVSTko8iuMBv0zyMpvc_uTSXZOFLzLkvbYONN2PGzSeNH4bzvepyYnQ2x4DUEfTctnXdz2HlhJ1kUQxv7B96j9lZ6Zln_eJb1LNIncdUgeMhBqhNze0jzeh3mxO7XH2qX9acOh9tUtHVBwvRP8csvRxwVDz1BbUp6OCTEONtyHkpUg_6nq8dF1FU-Q481IVMkU1j3jbP7jTm4KnKtlx0SneNn-WfRmyaqXZY_Zj3ytFBkw6ZlE9wfeV5Uh_U1HOg4eHtneEGL8lsAn0RnecerWRuGUNdt9nvtEELhQ8HoAMwzyHH97zHcJGUaGOmsognAl1PLKxZG4lEG-tzSi5nHJf455XC\" rel=\"nofollow\" target=\"_blank\"><strong>X<\/strong><\/a>.<strong>\u00a0<\/strong><\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company\u2019s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the \u201cRisk Factors\u201d section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.<\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <br \/>\n        <strong>Media<\/strong><br \/>\n        <br \/>Amanda Sheldon, Head of Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w469QpqKld29-AkSpTIFNlzZd2FvbtRsVQVs-0i6DyyD4ckoKwSHzgKnjGKH6NzChU4U8YgMRyZFQ8Gj1wU6fzozruz4DfOJPFcQtVghfOlTJ6vga5ZA_JrGgDGKkYL2R0z8CqXX1pD2V7MSTjQb98Bp0r8gI9f37TlcmcsmLQEgf8Q7aMBjE4DjBhJV3weLSo3vIS_xJxLu4jEmYlrVgGAwo-NelqVCpfdeK9HFil6ZREYiQs2LKDCqjz97IKANvXsx3WhVmmds3knPtpzfNw==\" rel=\"nofollow\" target=\"_blank\"><strong>media@arcutis.com<\/strong><\/a><\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Brian Schoelkopf, Head of Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TbvQw4Ekt4Bp8w1lv2N7qNYH38hdzh5_f4HoaU8YTzqJnK5kO-S0XPf6gCh40Jylik6pLrVubEjstkIxkZgBRKxNPU4k1Bcn7YI0Wd_AGxl8KfI3krZjOyzSql68G22c-Z_DLjf-8riq3-U9FUfOGxjt64LrquTz78rgQcAObAq285sTGCHrUmH29sqe4nbgtWvehVtD9mOxyhQAbkpAr4SDrYIrmnrxFPTdoT7C5BaW_3kFlXKyhMB3ixAEn3ndufeQpkbMC0ckXb9aOXaLNtMbKOJAexxx41EF2acqg2tPKaoOGvTCnBvpqynurew3KCcYP0UoCkrKoet-LjcsX0UMrlpi0FHXR2hZ7wBHMvmgOD-ba_jSILl2CPWziW_FGBA0XEu5SqEC28BWv31sRztcjNMqdcjBn9wJKIHwP4NFhYB0lj8sNuS3C5TPfg-doW5jCUcKMGMVPspLs7r4lfC5OzHoSD6aIxTamtYBHsQ=\" rel=\"nofollow\" target=\"_blank\"><strong>ir@arcutis.com<\/strong><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzAwMiM3MTcwMzY2IzIxOTQwNTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmZkOTQ5YTItZTdkMS00MzFiLWExNGEtMzI3Y2Y3YWUzZTk1LTEyMDU2MDMtMjAyNS0wOS0yOS1lbg==\/tiny\/Arcutis-Biotherapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025 financial results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will also host a virtual Investor Day the same day at 10:30 a.m. ET. In addition to discussing third quarter 2025 financial results, the Investor Day will feature: An in-depth look into the Company\u2019s strategy for long-term, sustained growth for ZORYVE\u00ae (roflumilast) A detailed review of clinical development activities and advancements for new ZORYVE indications and ARQ-234 An overview of the Company\u2019s capital allocation strategy and financial outlook The event will feature presentations from Arcutis &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-890396","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025 financial results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will also host a virtual Investor Day the same day at 10:30 a.m. ET. In addition to discussing third quarter 2025 financial results, the Investor Day will feature: An in-depth look into the Company\u2019s strategy for long-term, sustained growth for ZORYVE\u00ae (roflumilast) A detailed review of clinical development activities and advancements for new ZORYVE indications and ARQ-234 An overview of the Company\u2019s capital allocation strategy and financial outlook The event will feature presentations from Arcutis &hellip; Continue reading &quot;Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-29T20:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzAwMiM3MTcwMzY2IzIxOTQwNTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025\",\"datePublished\":\"2025-09-29T20:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\\\/\"},\"wordCount\":562,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNzAwMiM3MTcwMzY2IzIxOTQwNTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\\\/\",\"name\":\"Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNzAwMiM3MTcwMzY2IzIxOTQwNTA=\",\"datePublished\":\"2025-09-29T20:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNzAwMiM3MTcwMzY2IzIxOTQwNTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNzAwMiM3MTcwMzY2IzIxOTQwNTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/","og_locale":"en_US","og_type":"article","og_title":"Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 - Market Newsdesk","og_description":"WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025 financial results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will also host a virtual Investor Day the same day at 10:30 a.m. ET. In addition to discussing third quarter 2025 financial results, the Investor Day will feature: An in-depth look into the Company\u2019s strategy for long-term, sustained growth for ZORYVE\u00ae (roflumilast) A detailed review of clinical development activities and advancements for new ZORYVE indications and ARQ-234 An overview of the Company\u2019s capital allocation strategy and financial outlook The event will feature presentations from Arcutis &hellip; Continue reading \"Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-29T20:03:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzAwMiM3MTcwMzY2IzIxOTQwNTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025","datePublished":"2025-09-29T20:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/"},"wordCount":562,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzAwMiM3MTcwMzY2IzIxOTQwNTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/","name":"Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzAwMiM3MTcwMzY2IzIxOTQwNTA=","datePublished":"2025-09-29T20:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzAwMiM3MTcwMzY2IzIxOTQwNTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzAwMiM3MTcwMzY2IzIxOTQwNTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-biotherapeutics-to-host-virtual-investor-day-and-report-third-quarter-2025-financial-results-on-october-28-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/890396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=890396"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/890396\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=890396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=890396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=890396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}